Ionis Pharmaceuticals (IONS) Income from Continuing Operations (2009 - 2026)

Ionis Pharmaceuticals' Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 92528000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 37.03% year-over-year to 92528000.0 in Q1 2026; TTM through Mar 2026 was 337336000.0, a 25.53% increase from a year earlier, with the FY2025 full-year figure at 391746000.0, up 12.72% from the prior year.
• Income from Continuing Operations grew to 92528000.0 in Q1 2026 per IONS's latest filing, from 239753000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 325419000.0 in Q4 2023 and bottomed at 239753000.0 in Q4 2025.
• The 5-year median for Income from Continuing Operations is 99275000.0 (2024), against an average of 71739470.59.
• Biggest YoY gain for Income from Continuing Operations was 965.43% in 2023; the steepest drop was 213.69% in 2023.
• Year by year, Income from Continuing Operations stood at 37602000.0 in 2022, then jumped by 965.43% to 325419000.0 in 2023, then sank by 130.51% to 99275000.0 in 2024, then slumped by 141.5% to 239753000.0 in 2025, then surged by 61.41% to 92528000.0 in 2026.
• Per Business Quant, the three latest IONS Income from Continuing Operations figures stand at 92528000.0 (Q1 2026), 239753000.0 (Q4 2025), and 128606000.0 (Q3 2025).